These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10697535)

  • 1. Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
    Boudny V; Murakami Y; Nakano S; Niho Y
    Anticancer Res; 1999; 19(6B):5203-6. PubMed ID: 10697535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
    Zhang L; Hung MC
    Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
    Langton-Webster BC; Xuan JA; Brink JR; Salomon DS
    Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cell signaling and CDDP resistance].
    Masumoto N; Nakano S
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):424-30. PubMed ID: 9063479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
    Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
    Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
    Boudny V; Nakano S
    Anticancer Res; 2003; 23(1A):7-12. PubMed ID: 12680188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
    Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
    Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.
    de Graaf TW; de Jong S; de Vries EG; Mulder NH
    Anticancer Res; 1997; 17(1A):369-75. PubMed ID: 9066679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
    Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
    Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
    Zhan M; Liu X
    Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin.
    Xie XK; Yang DS; Ye ZM; Tao HM
    Cancer Invest; 2006 Feb; 24(1):1-8. PubMed ID: 16466985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
    Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin represses transcriptional activity from the minimal promoter of the O6-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-2-chloroethyl)-3-nitrosourea.
    Sato K; Kitajima Y; Nakagawachi T; Soejima H; Miyoshi A; Koga Y; Miyazaki K
    Oncol Rep; 2005 May; 13(5):899-906. PubMed ID: 15809756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
    Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
    Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress.
    Kim HJ; Hwang JY; Kim HJ; Choi WS; Lee JH; Kim HJ; Chang KC; Nishinaka T; Yabe-Nishimura C; Seo HG
    Clin Cancer Res; 2007 May; 13(9):2577-83. PubMed ID: 17473186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.